The market is $12bn - $13bn if you include the other drugs on the market competing with Lyrica, and growing at 6% each year.
- Forums
- ASX - By Stock
- Ann: Zeliras diabetic nerve pain drug outperforms Lyrica
The market is $12bn - $13bn if you include the other drugs on...
-
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ZLD (ASX) to my watchlist
(20min delay)
|
|||||
Last
70.0¢ |
Change
0.040(6.06%) |
Mkt cap ! $7.943M |
Open | High | Low | Value | Volume |
66.0¢ | 70.0¢ | 66.0¢ | $373 | 544 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 14642 | 70.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
75.0¢ | 4147 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 14642 | 0.700 |
2 | 3025 | 0.660 |
2 | 10910 | 0.650 |
1 | 2000 | 0.640 |
1 | 1600 | 0.625 |
Price($) | Vol. | No. |
---|---|---|
0.750 | 4147 | 3 |
0.785 | 343 | 1 |
0.790 | 1265 | 1 |
0.795 | 6192 | 1 |
0.800 | 102 | 2 |
Last trade - 12.23pm 12/11/2024 (20 minute delay) ? |
Featured News
ZLD (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online